10-Q: TG Therapeutics Reports Strong Q2 2026 Growth

TG Therapeutics announces significant revenue increase driven by BRIUMVI sales and positive clinical trial data for subcutaneous formulation and azer-cel.

Summary

• TG Therapeutics reported strong financial results for the second quarter of 2026, with total revenue reaching $240.3 million, a substantial increase from $141.1 million in the same period last year.
• Product revenue, primarily from BRIUMVI, grew to $235.8 million, up from $138.8 million in Q2 2025, reflecting increased market penetration in the U.S. and sales to the ex-U.S. partner, Neuraxpharm.
• Research and Development (R&D) expenses increased significantly to $95.3 million from $31.8 million, largely due to manufacturing expenses for subcutaneous development and other R&D activities.
• Selling, General, and Administrative (SG&A) expenses also rose to $82.1 million from $55.6 million, driven by marketing spend and personnel costs related to BRIUMVI commercialization.
• The company reported net income of $7.8 million for the quarter, a decrease from $28.2 million in the prior year, impacted by higher operating expenses and increased interest expense.
• Positive topline results were announced for the Phase 3 ENHANCE trial for BRIUMVI's consolidated single infusion regimen and for the Phase 1 trial of subcutaneous BRIUMVI.
• The company anticipates its existing cash, cash equivalents, and investment securities, along with projected future revenues, will be sufficient to fund operations for more than twelve months.
• TG Therapeutics does not currently expect to need additional capital but may seek financing for strategic initiatives.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth driven by BRIUMVI sales and promising clinical trial updates, although increased R&D and SG&A expenses are noted.

Positives

• Total revenue increased by 70% to $240.3 million for the three months ended June 30, 2026, compared to $141.1 million for the same period in 2025.
• Product revenue, net, increased by 70% to $235.8 million for the three months ended June 30, 2026, compared to $138.8 million for the same period in 2025.
• Gross margin on BRIUMVI U.S. net product revenue remained strong at approximately 87% for the three months ended June 30, 2026.
• Positive topline results were announced for the Phase 3 ENHANCE trial evaluating a consolidated single infusion regimen for BRIUMVI.
• Positive pharmacokinetic, pharmacodynamic, safety, and tolerability data were announced from the Phase 1 clinical trial for subcutaneous BRIUMVI.
• The company anticipates its existing cash and investments will be sufficient to fund operations for more than twelve months.
• The company announced the initiation of a Phase 2 clinical trial for BRIUMVI in adults with treatment-resistant schizophrenia.

Negatives

• Net income decreased to $7.8 million for the three months ended June 30, 2026, from $28.2 million for the same period in 2025.
• Total costs and expenses increased by 106% to $218.7 million for the three months ended June 30, 2026, compared to $106.3 million for the same period in 2025.
• Research and development expenses increased by 200% to $95.3 million for the three months ended June 30, 2026, compared to $31.8 million for the same period in 2025.
• Selling, general, and administrative expenses increased by 48% to $82.1 million for the three months ended June 30, 2026, compared to $55.6 million for the same period in 2025.
• Interest expense increased significantly to $16.6 million for the three months ended June 30, 2026, from $6.7 million for the same period in 2025, due to the new term loan facility.
• A loss on extinguishment of debt of $9.2 million was recorded in the six months ended June 30, 2026, related to the refinancing of the Initial Term Loan.

Risks

• The company faces substantial competition in the RMS market, which could impact BRIUMVI's market acceptance and commercial opportunity.
• Regulatory approvals for product candidates may be subject to limitations or post-marketing requirements, potentially impacting commercialization.
• Future product candidates may cause undesirable side effects that could lead to regulatory action or negatively impact commercial potential.
• The incidence and prevalence of target patient populations may be smaller than estimated, affecting revenue and profitability.
• Unfavorable pricing regulations or third-party payor coverage and reimbursement policies could harm the business.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• The company has a history of losses and its ability to maintain future profitability remains uncertain.
• The company may need to raise additional capital, and failure to do so could lead to delays or reductions in development or commercialization efforts.

Future Outlook

The company anticipates that its existing cash, cash equivalents, and investment securities, together with projected future revenues, will be sufficient to fund operations and meet its liquidity needs for more than twelve months. TG Therapeutics does not currently expect to need to raise additional capital but may seek financing for strategic initiatives.

Management Comments

• We will continue to invest in our research and development programs and in selling, general and administrative activities to support our commercialization efforts, while maintaining discipline around overall expense growth relative to revenue.
• Based on our current operating plan and results, we anticipate that our existing cash, cash equivalents, and investment securities, together with projected future revenues, will be sufficient to fund operations and meet our liquidity needs for more than twelve months after the date of filing of this Quarterly Report on Form 10-Q.
• We do not currently expect to need to raise additional capital to fund our ongoing operations, but may from time to time seek additional financing to support strategic initiatives, including potential business development activities.

Industry Context

StockSavvy.ai notes that TG Therapeutics is operating in the competitive relapsing forms of multiple sclerosis (RMS) market. The company's strategy to expand BRIUMVI's adoption relies on continued execution in access and site-of-care pathways, facing challenges from established prescribing practices, payer coverage, and competitive dynamics.

Comparison to Industry Standards

• BRIUMVI's one-hour infusion time and twice-annual dosing schedule are positioned as competitive advantages within the anti-CD20 therapeutic class.
• The company's R&D spending as a percentage of revenue has increased, reflecting investment in pipeline development, particularly for subcutaneous formulations and new indications.
• The company's gross margin on U.S. BRIUMVI sales of approximately 87% appears strong compared to industry averages for similar biologic therapies, though overall gross margin is lower due to sales to the ex-U.S. partner.

Legal Proceedings

• The company and its subsidiaries are not a party to, and its property is not the subject of, any material pending legal proceedings.

Related Party Transactions

• The company has an Office Agreement with Fortress Biotech, Inc. (FBIO) for office space, which is treated as a related party transaction.

Stakeholder Impact

• Shareholders may benefit from the strong revenue growth of BRIUMVI and positive clinical trial updates, but also face risks from increased operating expenses and stock price volatility.
• Patients with relapsing forms of multiple sclerosis may benefit from BRIUMVI's efficacy and convenient dosing schedule, with potential for improved patient convenience through a subcutaneous formulation.
• Healthcare providers will continue to evaluate BRIUMVI's clinical profile and competitive positioning.
• Payers will continue to assess coverage and reimbursement policies for BRIUMVI.

Next Steps

• Continue to invest in R&D programs and SG&A activities to support BRIUMVI commercialization.
• Advance the development of subcutaneous ublituximab, with topline data from the Phase 3 trial expected around year-end 2026 or first quarter 2027.
• Continue advancing azer-cel development for autoimmune diseases.
• Explore potential in-licensing and acquisition opportunities for pipeline enhancement.
• Continue to expand prescriber awareness, increase penetration across infusion centers and neurology practices, and secure payer coverage for BRIUMVI.
• Initiate Phase 2 clinical trial for BRIUMVI in treatment-resistant schizophrenia.

Key Dates

Recommendation

TG Therapeutics shows strong revenue growth driven by BRIUMVI and positive clinical developments. However, the significant increase in R&D and SG&A expenses, coupled with a decrease in net income and substantial debt, warrants a cautious 'hold' rating. Investors should monitor the commercial uptake of BRIUMVI and the progress of the subcutaneous formulation and azer-cel trials.

Keywords

TG Therapeutics, BRIUMVI, ublituximab, Multiple Sclerosis, biotechnology, oncology, CAR T therapy, clinical trials